1. Home
  2. THRM vs GERN Comparison

THRM vs GERN Comparison

Compare THRM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gentherm Inc

THRM

Gentherm Inc

HOLD

Current Price

$33.07

Market Cap

1.1B

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.65

Market Cap

900.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
THRM
GERN
Founded
1991
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
900.1M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
THRM
GERN
Price
$33.07
$1.65
Analyst Decision
Buy
Buy
Analyst Count
4
6
Target Price
$40.25
$2.90
AVG Volume (30 Days)
353.4K
16.7M
Earning Date
05-22-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.59
N/A
Revenue
$554,979,000.00
N/A
Revenue This Year
$3.43
$32.27
Revenue Next Year
$3.61
$60.16
P/E Ratio
$56.53
N/A
Revenue Growth
50.16
N/A
52 Week Low
$22.75
$1.04
52 Week High
$39.48
$2.01

Technical Indicators

Market Signals
Indicator
THRM
GERN
Relative Strength Index (RSI) 47.58 51.38
Support Level $32.61 $1.20
Resistance Level $35.94 $1.68
Average True Range (ATR) 1.51 0.15
MACD 0.33 -0.00
Stochastic Oscillator 64.02 33.35

Price Performance

Historical Comparison
THRM
GERN

About THRM Gentherm Inc

Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: